Artimplant Interim Report January 1 - March 31, 2007

Artimplant Interim Report January 1 - March 31, 2007

Västra Frölunda, Sweden, May 3, 2007

• Net revenue of SEK 3.9 million (1.1)*
• Net loss of SEK 2.9 million (10.4)
• Earnings per share of SEK -0.05 (SEK -0.17)
• Strong sales increase for Artelon® CMC Spacer - around 1,300 (400) units were
sold to end-customers during Q1 2007
• More than 4,000 patients had been treated with Artelon® devices through to Q1
2007


* Figures in brackets refer to the corresponding period last year.

The Company will not hold any conference call this quarter.

For additional information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.


Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.